Agustí C, Xaubet A, Agustí A G, Roca J, Ramirez J, Rodriguez-Roisin R
Departament d'Anatomia Patològica, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Spain.
Eur Respir J. 1994 Apr;7(4):643-50. doi: 10.1183/09031936.94.07040643.
The purpose of this study was to analyse the information provided by different techniques used in the assessment of patients with idiopathic pulmonary fibrosis (IPF) and their role in the prediction of lung function decline with the decline. Twenty seven subjects with IPF (55 +/- 14 (mean +/- SD) yrs) were studied at the initial staging. Nineteen of them (70%) were included in a follow-up over 3 yrs (32 +/- 6 months), whilst the remaining 8 patients were lost to follow-up. During the period of the study, 6 of the 19 patients died. A significant correlation between diffusing capacity of the lungs for carbon monoxide (DLCO) (and carbon monoxide transfer coefficient (KCO) = DLCO/alveolar volume (VA)) and the increase in alveolar-arterial oxygen tension difference (A-aPO2) during exercise (delta A-aPO2) was observed at diagnosis (r = -0.58). Despite the treatment with prednisone (1 mg.kg-1 daily during 4 weeks, tapered to an individualized maintenance daily dose of 15-30 mg), the 13 patients controlled throughout the whole period of the study showed a marked impairment in lung volumes; forced vital capacity (FVC) -0.46 +/- 0.09 l, from 69 +/- 16 to 52 +/- 11% of predicted, and total lung capacity (TLC) -0.39 +/- 0.11 l, from 75 +/- 16 to 62 +/- 14%, and in DLCO -0.6 +/- 0.2 mmol.min-1.kPa-1, from 56 +/- 15 to 47 +/- 18%, predicted. By contrast, both mean arterial oxygen tension (PaO2) and A-aPO2 at rest remained unchanged throughout the 3 yrs follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究的目的是分析用于评估特发性肺纤维化(IPF)患者的不同技术所提供的信息,以及它们在预测肺功能随时间下降方面的作用。对27例IPF患者(55±14(均值±标准差)岁)进行了初始分期研究。其中19例(70%)纳入了为期3年以上(32±6个月)的随访,其余8例患者失访。在研究期间,19例患者中有6例死亡。在诊断时观察到肺一氧化碳弥散量(DLCO)(及一氧化碳转移系数(KCO)=DLCO/肺泡容积(VA))与运动期间肺泡-动脉氧分压差(A-aPO2)的增加(ΔA-aPO2)之间存在显著相关性(r=-0.58)。尽管使用泼尼松进行了治疗(4周内每日1mg·kg-1,逐渐减量至个体化维持每日剂量15-30mg),但在整个研究期间病情得到控制的13例患者的肺容积仍有明显损害;用力肺活量(FVC)下降0.46±0.09L,从预测值的69±16%降至52±11%,肺总量(TLC)下降0.39±0.11L,从预测值的75±16%降至62±14%,DLCO下降0.6±0.2mmol·min-1·kPa-1,从预测值的56±15%降至47±18%。相比之下,在3年的随访期间,静息时的平均动脉血氧分压(PaO2)和A-aPO2均保持不变。(摘要截选至250字)